Von Willebrand Disease and Pregnancy

Muhammad Wasif Saif1, Carmen Allegra2

  • 1National Cancer Institute-Naval Medical Center in Bethesda, Md.

Consultant
|April 22, 2022
PubMed

A 26-year-old woman (gravida 1) was seen when she was 33½ weeks pregnant. She was healthy except for easy bruising, which had been a problem since childhood. The patient did not have nosebleeds or prolonged bleeding after toothbrushing, flossing, or minor cuts. Menarche had occurred at age 13, with a 28-day cycle. Her heavy menstrual periods usually lasted 7 to 10 days. She underwent tonsillectomy and adenoidectorny at age 7 and bilateral bunionectomy at age 20; hemorrhage did not occur after the operations. The patient did not smoke or abuse drugs or alcohol. She took no medications except for prenatal vitamins. Mild von Willebrand disease (vWD) had recently been diagnosed in her mother. Her father had anemia of unknown cause; his family history included thalassemia, and his father had Hodgkin disease that was diagnosed when he was 30 years old. Her 23-year-old brother was healthy and had no bleeding disorders. The patient appeared well-nourished and was in no distress. Vital signs were stable, and site was afebrile. Heart sounds were normal; lungs were clear. Her abdomen was soft and rumtender. There was no spine tenderness, mucosal bleeding, ocular hemorrhage, or skin bruising. Because of the patient's history of easy bruising and heavy menstrual bleeding and her mother's recently diagnosed vWD, testing for the disorder was ordered. Laboratory results revealed von Willebrand factor (vWF) antigen activity of 75 U/dL, activated partial thromboplastin time (aPTT) of 32 seconds, factor VIII activity of 100%, and bleeding time of 9 minutes. (Normal values are vWF antigen level, 50 to 200 U/dL; aPTT) 20 to 32 seconds; factor VIII activity, 60% to 150%; and bleeding time, 5.5 minutes.) A ristocetin-induced platelet aggregation test did not show aggregation at tow concentrations of ristocetin, and vWF multimers showed a normal distribution. These laboratory data suggested that the patient had type 1 vWD. She was closely monitored during the rest of her pregnancy. At full term, the patient went into labor. About 1 to 2 hours before the delivery, she was given intravenous desmopressin at a dosage of 0.3 μg/kg in 50 mL of saline over 30 minutes. When vaginal bleeding (approximately 150 mL) occurred on postpartum day 3, the patient was given nasal desmopressin and advised to limit her physical activity. No excessive bleeding occurred thereafter.

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.3K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
949
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
42
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
662
Rh Blood Group01:19

Rh Blood Group

The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
2.0K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.3K